English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 906275 Online Users : 848
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
National Institute of Cancer Research
Kuan-Te Li(1997-2004)
--Conference Papers/Meeting Abstract
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
NHRI
>
National Institute of Cancer Research
>
Kuan-Te Li(1997-2004)
>
Conference Papers/Meeting Abstract
>
Browse By Title
Browse By Authors
Browse By Date
Browse By Data Type
Loading...
Siblings
Periodical Articles
[
3
/3]
Collection Statistics
Item counts issued in 3 years:0(0.00%)
Items With Fulltext:1(33.33%)
Download counts of the item
Download times greater than 0:1(100.00%)
Download times greater than 100:1(100.00%)
Total Bitstream Download Counts:495(9.54%)
Last Update: 2024-12-01 10:22
Top Upload
Loading...
Top Download
Loading...
Recent Submissions
Results of Phase II trial of AUY922...
KRAS mutation status-stratified ran...
Impact of ROS1, ALK, and/or MET exp...
Jump to a point in the index:
(Choose year)
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1985
1980
1975
1970
1960
1950
(Choose month)
January
February
March
April
May
June
July
August
September
October
November
December
Or type in a year:
Ordering With Most Recent First
Show Oldest First
Showing items 1-3 of 3. (1 Page(s) Totally)
1
View [
10
|
25
|
50
] records per page
Date
Title
Relation
2016-02
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 134.
2014-01
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial
Journal of Clinical Oncology. 2014 Jan;32(3 Suppl):Abstract number 267.
2013-05
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number 4018.
Showing items 1-3 of 3. (1 Page(s) Totally)
1
View [
10
|
25
|
50
] records per page
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback